BioPharm Insight™ Reports the Alzheimer's Association International Conference (AAIC) is Focusing on Early Intervention

Vancouver : Canada | Jul 30, 2012 at 2:32 PM PDT

Source: PRWeb

XX XX

Views: Pending

Vancouver earlier this month and found a significant focus on early intervention. Pfizer announced that bapineuzumab Phase III top-line results indicated the drug was not clinically effective in mild-to-moderate Alzheimer’s patients who are carriers of the ApoE4 gene. Baxter’s Phase III GAP trial

Bristol-Myers Squibb plans Phase III avagacestat trial

Avanir’s AVP-923 in AD associated agitation

Sales forecasts for Namenda, Aricept, Exelon, Bapineuzumab and Solanezumab

Download the full report

About BioPharm Insight

BioPharm Insight is the definitive guide to the global biopharma community. BioPharm Insight provides clients with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit http://www.biopharminsight.com.

About Infinata, Inc.

Featuring a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services, Infinata provides personalized technology solutions to turn information into insight. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit http://www.infinata.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/7/prweb9744093.htm